A control observation of refractory Tourette syndrome treated with risperidone

Objective:To explore the efficacy and safety of risperidone in treatment of refractory Tourette syndrome.Method:141 patients with refractory Tourette syndrome were randomly allocated to two groups,risperidone group(n=71)treated with enly risperidone and control group(n=70)freated with haloperidol or haloperidol plus other medrcine for a 8-week open-control study.Clinical efficacy was evaluated by Yale global tic severity scale(YGTSS)and Achendach child behavior checklist(CBCL),and the safety was assessed by treatment emergent symptom scale(TESS),at baseline and after 4 and 8 weeks treatment.Results:The symptoms improved in both groups.The response rate was 56.3% in risperidone group,markedly higher than control group(32.9%)(χ2=8.212,P0.01),while the total YGTSS score in risperidone group was significantly lower than that in control group(39.97±15.62vs 49.84±13.91,P0.01)at 4 weeks.Higher response rate(71.8% vs 51.4%,χ2=6.357,P0.05),lower total YGTSS score(17.20±11.24 vs 24.97±10.74,P0.05)and higher YGTSS reduction rate(76.55%±14.73% vs 66.86%±14.28%,P0.01)were in risperidone group compared with control group after 8 weeks.The total CBCL score in both groups reduced significantly in 4 and 8 weeks(P0.05).The TESS score in risperidone group was observably lower than that in control group at 4 and 8 weeks(P0.01).Conclusion:Risperidone has a positive efficacy and less side effects in treatment of refractory Tourette syndrome.